Technology | Nuclear Imaging | October 14, 2015

Gamma Medica Receives CE Mark for LumaGEM Molecular Breast Imaging System

Approval brings patients in Europe one step closer to improved screening for dense breast tissue

Gamma Medica, LumaGEM MBI system, molecular breast imagign, CE Mark approval

Image courtesy of Gamma Medica

October 14, 2015 — Gamma Medica Inc. announced the CE Mark approval allowing for the sale and distribution of the LumaGEM Molecular Breast Imaging (MBI) system within the European Economic Area (EEA). Gamma Medica is finalizing distribution partners in strategic markets across the EEA.

Breast cancer is the most common cancer affecting women in Europe, with nearly one in 10 women developing breast cancer before the age of 80. Dense breast tissue has been linked to an increased risk of breast cancer and a decrease in mammography sensitivity. These factors impact early detection efforts as both cancer and dense tissue appear white on the mammogram.

The LumaGEM MBI system addresses the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer for the 50 percent of women with dense breast tissue. The system has been commercially available in the United States since obtaining approval by the U.S. Food and Drug Administration (FDA) in 2011.

A recent study conducted by Mayo Clinic, and published in two articles in the American Journal of Roentgenology (AJR) in 2015 determined that the addition of MBI, such as the LumaGEM MBI system, to an annual mammogram screening demonstrated a near 400 percent increase in invasive breast cancer detection rates. The combination also demonstrated a 50 percent reduction in biopsies and a subsequent 15 percent lower cost per cancer detected than screening with mammography alone.

The growing awareness of the limitations of mammography screening for women with dense breast tissue and the necessity for an effective adjunct screening technology led to the creation of LumaGEM MBI. Unlike mammography, tomosynthesis, ultrasound and magnetic resonance imaging (MRI) — all of which are anatomical imaging tests — MBI is a functional imaging modality that highlights metabolic activity in the breast and detects tumors not visible on a mammogram due to tissue density.

It is important for women to discuss with their doctors if MBI is an appropriate screening method for them. In addition to women with dense breast tissue or suspicious lesions, MBI may also be valuable for high-risk patients with a family history of breast cancer, patients who have tested positive for BRCA1 or BRCA2 genes, symptomatic patients, patients with cosmetic augmentation or patients who cannot receive an MRI.

For more information: www.gammamedica.com

Related Content

Mayo Clinic Installing First FDA-Approved Clinical 7T MRI
News | Magnetic Resonance Imaging (MRI) | October 20, 2017
Mayo Clinic in Rochester, Minn., will have the first clinical 7-Tesla magnetic resonance imaging (MRI) scanner in North...
Edward-Elmhurst Health Completes CR-to-DR Conversion With Carestream Systems
News | Digital Radiography (DR) | October 20, 2017
October 20, 2017 — Edward-Elmhurst Health of Naperville, Ill., has installed four Carestream DRX-Evolution Plus and D
Median Technologies Brings iBiopsy Platform to The Liver Meeting
News | Advanced Visualization | October 20, 2017
October 20, 2017 — Median Technologies announced that it will participate in The Liver Meeting, the annual meeting of
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
Sonoscanner Obtains FDA Approval for U-lite EXP Portable Ultrasound
Technology | Ultrasound Imaging | October 18, 2017
Sonoscanner recently announced it received U.S. Food and Drug Administration (FDA) approval to market its new...
Study Examines Characteristics of Mobile Mammography Patients
News | Mammography | October 18, 2017
Significant differences were found among women receiving mammography at a cancer center versus those visiting a mobile...
HealthMyne QIDS 3.0 Platform Addresses Incidental Findings Workflow
Technology | PACS Accessories | October 18, 2017
October 18, 2017 — HealthMyne announced the release of QIDS (Quantitative Imaging Decision Support) 3.0 with the Inci
Carestream Introduces Wireless Tablet-Based DR Converter
Technology | Digital Radiography (DR) | October 18, 2017
October 18, 2017 — Carestream Health looks to make converting to...
Machine Learning Identifies Breast Lesions Likely to Become Cancer
News | Artificial Intelligence | October 18, 2017
A machine learning tool can help identify which high-risk breast lesions are likely to become cancerous, according to a...
Technology | Ultrasound Imaging | October 17, 2017
Philips announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the new...
Overlay Init